Media Center
- No
-
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
- Title
- Author
- Time uploaded
- Views
- Likes
- 48
- News Article
- News Article Interview of Dr. Jin-San Yoo, CEO of PharmAbcine with informa
- Manager
- 14 Jan 2019
- Views1374
- 1
- 47
- News Article
- News Article PharmAbcine, a clinical stage immuno-oncology company announced that PharmAbcine is so proud to be a sponsor of the 11th COGNO Annual Scientific Meeting,
- Manager
- 14 Jan 2019
- Views1287
- 1
- 46
- News Article
- News Article PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer...
- Manager
- 14 Jan 2019
- Views1202
- 1
- 45
- News Article
- News Article PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer...
- 관리자
- 14 Jan 2019
- Views1111
- 0
- 44
- News Article
- News Article PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer...
- Manager
- 14 Jan 2019
- Views1227
- 1
- 43
- News Article
- News Article PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer...
- Manager
- 14 Jan 2019
- Views1079
- 1
- 42
- News Article
- News Article PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is attending ASCO 2018.
- Manager
- 14 Jan 2019
- Views1025
- 1
- 41
- News Article
- News Article PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer...
- 관리자
- 14 Jan 2019
- Views925
- 0
- 40
- News Article
- News Article PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer...
- Manager
- 14 Jan 2019
- Views963
- 1
- 39
- News Article
- News Article PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001 for Glioblastoma Multiforme.
- Manager
- 14 Jan 2019
- Views1204
- 1